United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 12

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 12 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCocrystal Pharma · 48

Strongest available pathSupernus Pharmaceuticals · +65.8%

Widest latest marginCryoport · 44.4%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1COCP · Nasdaq

Cocrystal Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007Tucker, Georgia$22.3M market cap

View full Companies Radar profile

48Cautious

Snapshot price$1.16as of page date

Monthly-close return-90.8%five-year window

FY2021 revenue$0.00BCocrystal Pharma, Inc.

Net margin-704.3%FY2021

P/E snapshot-2.0xone ratio, not a verdict

Prism attention11.7%share across these five

Filing track recordRevenue, USD billions

-73.6%

FY2012–FY2021 · 4 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2012 · CAGR -35.8%

52-week position21% through range

$0.76$2.67

News mentions422

Community mentions0partial coverage

U.S.-scope patents206

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position3/100
Capital-event signal89/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2CYRX · Nasdaq

Cryoport

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Brentwood, Tennessee$810.4M market cap

View full Companies Radar profile

48Cautious

Snapshot price$16.00as of page date

Monthly-close return-75.9%five-year window

FY2025 revenue$0.18BCryoport, Inc.

Net margin44.4%FY2025

P/E snapshot-24.1xone ratio, not a verdict

Prism attention25.8%share across these five

Filing track recordRevenue, USD billions

-20.9%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2020, FY2022, FY2023 · CAGR -5.7%

52-week position87% through range

$7.61$17.20

News mentions933

Community mentions0partial coverage

U.S.-scope patents240

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal57/100
Management stability90/100
Market position15/100
Capital-event signal64/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 0 asset-acquisition events and 12 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3EVFM · OTC

Evofem

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009San Diego, California$1.1M market cap

View full Companies Radar profile

48Cautious

Snapshot price$0.01as of page date

Monthly-close return-100.0%five-year window

FY2025 revenue$0.02BEvofem Biosciences, Inc.

Net margin1.9%FY2025

Prism attention16.2%share across these five

Filing track recordRevenue, USD billions

+10.8%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.3%

52-week position50% through range

$0.00$0.02

News mentions587

Community mentions121partial coverage

U.S.-scope patents70

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position13/100
Capital-event signal72/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 12 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4CYPH · Nasdaq

Leap Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2011Cambridge$194.3M market cap

View full Companies Radar profile

48Cautious

Snapshot price$1.82as of page date

Monthly-close return-95.4%five-year window

FY2022 revenue$0.00BCYPHERPUNK TECHNOLOGIES INC.

Net margin-3639.7%FY2022

P/E snapshot2.9xone ratio, not a verdict

Prism attention16.1%share across these five

Filing track recordRevenue, USD billions

+0.0%

FY2020–FY2022 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.0%

52-week position45% through range

$0.27$3.70

News mentions583

Community mentions0partial coverage

U.S.-scope patents44

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal58/100
Management stability90/100
Market position5/100
Capital-event signal75/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SUPN · Nasdaq

Supernus Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Rockville, Maryland$2.57B market cap

View full Companies Radar profile

48Cautious

Snapshot price$44.21as of page date

Monthly-close return+65.8%five-year window

FY2025 revenue$0.72BSUPERNUS PHARMACEUTICALS, INC.

Net margin-5.4%FY2025

P/E snapshot9.9xone ratio, not a verdict

Prism attention30.2%share across these five

Filing track recordRevenue, USD billions

+38.2%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 8.4%

52-week position10% through range

$42.45$59.68

News mentions1.1K

Community mentions16partial coverage

U.S.-scope patents541

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal73/100
Management stability90/100
Market position16/100
Capital-event signal38/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 12 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Supernus Pharmaceuticals

+65.8%

Cryoport

-75.9%

Cocrystal Pharma

-90.8%

Leap Therapeutics

-95.4%

Evofem

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Supernus Pharmaceuticals

$0.72B

Cryoport

$0.18B

Evofem

$0.02B

Cocrystal Pharma

$0.00B

Leap Therapeutics

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Cryoport

44.4%

Evofem

1.9%

Supernus Pharmaceuticals

-5.4%

Cocrystal Pharma

-704.3%

Leap Therapeutics

-3639.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Supernus Pharmaceuticals

30.2%

Cryoport

25.8%

Evofem

16.2%

Leap Therapeutics

16.1%

Cocrystal Pharma

11.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Supernus Pharmaceuticals leads the conversation

It holds 30.2% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.72B.

Price path

Supernus Pharmaceuticals leads the available price paths

Its monthly-close return is +65.8% for the five-year window. At the other end, Evofem is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Cryoport has the widest latest margin

Its FY2025 net margin is 44.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cryoport shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -24.1x while its five-year window price return is -75.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CYRX

Cryoport

933available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Legal, arbitration & regulatory

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+35.8%148 latest 12m vs 109 prior 12m

Machine-classified coverage tone

94.4% positive+0.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 36stock price 12stem cell banking 10stock indices 8stock surge 8stock plunge 7gene delivery systems 7equity markets 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-12 · trend and themes shown through 2026-06

Areas of research · SUPN

Supernus Pharmaceuticals

1,090available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+5.4%233 latest 12m vs 221 prior 12m

Machine-classified coverage tone

85.5% positive-0.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 17company valuation 16ssri effectiveness trials 14treatment-resistant depression studies 12antidepressant response rates 10crude oil prices 10depression treatment outcomes 9stock price 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-07-13–2026-06-15 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

EVFM

Evofem

121 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 121 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

COCP

Cocrystal Pharma

through 2026-04-08

Earnings releases 3Company announcements 2Leadership changes 2

2026-04-08
Earnings releases
Equities research analysts at Zacks Research issued their FY2028 earnings per share estimates for Cocrystal Pharma in a report released on Tuesday, April 7th.
2024-09-30
Leadership changes
He served as chief executive officer and a director of Cocrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016,
2023-11-27
Company announcements
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CYRX

Cryoport

through 2026-05-04

Earnings releases 25M&A 4Business contracts 1Company announcements 1Lawsuits 1

2026-05-04
Earnings releases
Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million , up 16% year-over-year.
2025-12-31
M&A
Cryoport, Inc, a temperature-controlled supply chain solution provider for the life sciences industry, has obtained Cell&Co BioServices, a bioservices business that offers biorepository, kitting, and logistics services to the same sector. The purchase price was $6.7 million.
2024-02-15
Company announcements
Cryoport has outlined aggressive expansion plans. Mark Sawicki, President and CEO of Cryoport Systems, told gasworld that it plans to open two new facilities in Houston and Belgium in the second and third quarters, with more expansion to come.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EVFM

Evofem

through 2026-02-07

Earnings releases 18M&A 11Leadership changes 5Business contracts 2

2026-02-07
M&A
The company moved into the women’s health market with the $100 million planned acquisition of Evofem Biosciences Inc., maker of the contraceptive gel Phexxi, which it reported on Dec. 12.
2026-02-01
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evofem Biosciences $11.39 million 0.10 $52.98 million ($0.06) -0.15
2025-03-26
Business contracts
including its July 2024 license agreement with Emirati pharmaceutical company Pharma 1 Drug Store, which plans to launch the hormone-free contraceptive vaginal gel in the UAE following approval by the Emirates Drug Establishment.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CYPH

Leap Therapeutics

through 2023-08-09

Company announcements 2Earnings releases 2M&A 2

2023-08-09
Earnings releases
Last quarter, Leap Therapeutics missed earnings estimates, reporting EPS of -$3.20 on estimates of -$0.86.
2023-06-20
Company announcements
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023.
2023-01-17
M&A
Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SUPN

Supernus Pharmaceuticals

through 2026-04-08

Earnings releases 22M&A 6Lawsuits 2Leadership changes 2Listing / IPO 2

2026-04-08
Asset acquisitions
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820 Apr 08, 2026, 1:20 AM ET
2025-11-04
Earnings releases
Total revenues $192.1 million
2025-07-28
M&A
On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 56–63. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cocrystal Pharma leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open Cocrystal Pharma in Companies Radar

Scale and margin leadership sit with Supernus Pharmaceuticals and Cryoport

Supernus Pharmaceuticals has the largest displayed latest revenue at $0.72B; Cryoport has the widest displayed latest margin at 44.4%.

Open Supernus Pharmaceuticals in Companies Radar Open Cryoport in Companies Radar

Comparisons

Strongest versus weakest available price path

Supernus Pharmaceuticals is +65.8% for its five-year window; Evofem is -100.0% for its five-year window.

Open Supernus Pharmaceuticals in Companies Radar Open Evofem in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.72B for Supernus Pharmaceuticals to $0.00B for Cocrystal Pharma. Entity and filing-period labels remain visible on the company cards.

Open Supernus Pharmaceuticals in Companies Radar Open Cocrystal Pharma in Companies Radar

Anomalies

Supernus Pharmaceuticals has the widest attention-readiness rank gap

It ranks #1 by measured news attention (30.2%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Supernus Pharmaceuticals in Companies Radar

Evofem shows a price-operating divergence to inspect

Its displayed filing-revenue change is +10.8% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Evofem in Companies Radar

Explanations

Attention measures coverage volume, not quality

Supernus Pharmaceuticals's 30.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Supernus Pharmaceuticals in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cocrystal Pharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open Cocrystal Pharma in Companies Radar

Stress-test the largest divergence before forming a view

Compare Evofem's profile with Supernus Pharmaceuticals's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Evofem in Companies Radar Open Supernus Pharmaceuticals in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.